ConductScience.org, home

Comparison · NCT01009060-5582e98e

GSK239512 vs Placebo: Number of Par. With Most Severe On-treatment Abnormal Electrocardiogram (ECG) Findings

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. GSK239512 vs Placebo: Number of Par. With Most Severe On-treatment Abnormal Electrocardiogram (ECG) Findings. Trial comparisons, record NCT01009060-5582e98e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01009060-5582e98e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4550.2690.653wilson
Risk in group 20.320.1720.516wilson
Risk difference, group 1 minus group 20.135-0.1350.382newcombe hybrid score
Risk ratio, group 1 over group 21.420.6832.95log
Odds ratio, group 1 over group 21.770.545.81log
Number needed to treat, for one more participant with the outcome on GSK239512 than on Placebo7.43from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1GSK239512
Par. received oral GSK239512 once daily for a period of 7 weeks (4 weeks titration and 3 weeks at maintenance). Par. started at a daily dose of 10 micrograms (μg) GSK239512 and titrated up weekly through successive dose levels of 20 μg, 40 μg up to a maximum dose of 80 μg according to the titration regimen.
1022OG001
Group 2PlaceboPar. received oral placebo tablet matching with GSK239512 once daily for a period of 7 weeks.825OG000

Outcome

Type
SECONDARY
Title
Number of Par. With Most Severe On-treatment Abnormal Electrocardiogram (ECG) Findings
Description
Triplicate 12-lead ECGs were obtained at Baseline (screening visit). Single 12-lead ECGs were obtained at each subsequent time point during the study. Abnormal ECG findings were presented for the most severe on-treatment result.
Time frame
Up to Day 59
Population
Safety Population. Only those participants who showed most severe on-treatment abnormal ECG findings are presented.

Source ClinicalTrials.gov

Trial

Title
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
NCT number
NCT01009060
Phases
PHASE2
Conditions
Schizophrenia
Interventions
GSK239512, Placebo
Lead sponsor
GlaxoSmithKline
Results first posted
2017-09-27

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01009060-5582e98e